Skip to main navigation
Skip to search
Skip to main content
Providence Home
Search content at Providence
Home
Profiles
Research and Focus Areas
Grants and Projects
Research
Awards
Targeting the PI3K/AKT/mTOR pathway in ovarian cancer
Fernanda Musa
, Robert Schneider
Cancer
Washington
Women & Children
Research output
:
Contribution to journal
›
Review article
›
peer-review
13
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Targeting the PI3K/AKT/mTOR pathway in ovarian cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Ovarian Cancer
100%
Clinical Trial
100%
PI3K/AKT/mTOR Pathway
100%
Overall Survival
20%
Carcinogenesis
20%
Female Genital Tract Cancer
20%
Mammalian Target of Rapamycin Inhibitor
20%
Anticipation
20%
First-Line Chemotherapy
20%
Kinase
20%
Protein Kinase B
20%
Diseases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Ovary Cancer
100%
Protein Kinase B
100%
First-Line Chemotherapy
20%
Overall Survival
20%
Female Genital Tract Cancer
20%
Mammalian Target of Rapamycin Inhibitor
20%
Carcinogenesis
20%
Diseases
20%